OmniAb Inc (OABI) Stock Forecast & Price Target

OmniAb is well positioned because its licensing model monetizes differentiated antibody discovery technology through upfront payments, milestones, and tiered royalties, creating a scalable, high-margin revenue stream with limited added cost. Management and analysts point to a >$500M annual B-cell screening market growing double digits, a ~$7B lab-in-the-loop opportunity, and meaningful royalty optionality from 425 active programs with 98% downstream economics, plus >$3B of potential milestones and ~3.4% average royalty rates. Near-term catalysts also look strong, with xPloration revenue expected at $2M–$3M in 2026 and nearly 20 partner data readouts through the end of 2027, while the Lilly collaboration adds validation and up to $370M in milestones.

OmniAb is vulnerable because much of its value depends on downstream milestones and royalties from partner assets, so delayed or failed approvals would directly pressure valuation and cash generation. The business also faces slower program adds if biopharma capital spending stays cautious in an uncertain macro environment, while commoditization, patent invalidation, or AI models that generate high-performing sequences de novo could erode demand for its animal-based platform. Although management highlights a clinical NPV framework and >200 assets outside the valuation, the company still depends on continued partner news flow, new deals, and adequate funding to advance assets, leaving the outlook exposed to execution and adoption risk.